CureVac N.V. Board of Directors

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Dr. Alexander Zehnder M.B.A., M.D.

Dr. Alexander Zehnder M.B.A., M.D.

CEO, MD & Member of Management Board

Dr. Malte Greune Ph.D.

Dr. Malte Greune Ph.D.

COO, Member of Management Board & MD

Mr. Thorsten Schuller

Mr. Thorsten Schuller

Head of Corporate Communications

Dr. Myriam Mendila M.D.

Dr. Myriam Mendila M.D.

Chief Scientific Officer, Head of R&D, MD & Member of the Management Board

Dr. Ulrike Gnad-Vogt M.D., Ph.D.

Dr. Ulrike Gnad-Vogt M.D., Ph.D.

Senior VP & Area Head of Oncology

Mr. Thaminda Ramanayake

Mr. Thaminda Ramanayake

Chief Business Officer & Member of Executive Board

Dr. Sarah Fakih

Dr. Sarah Fakih

Vice President Corporate Communications & Investor Relations

Mr. Axel-Sven Malkomes

Mr. Axel-Sven Malkomes

CFO & Member of Executive Board

Slavica Stevanovic-Heck

Slavica Stevanovic-Heck

Head of Human Resources

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.